Trials / Completed
CompletedNCT00383149
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- R-Pharm · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone | Intravenous Infusion (IV), 32 mg/m\^2 every 21 days. |
| DRUG | Cetuximab | Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour. |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2006-10-02
- Last updated
- 2016-03-10
- Results posted
- 2010-10-19
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00383149. Inclusion in this directory is not an endorsement.